Lido Advisors
ADMA icon

Lido Advisors’s ADMA Biologics ADMA Stock Holding History

Lido Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Buy
24,174
+4,067
+20% +$37.1K ﹤0.01% 1965
2026
Q1 		$181K Buy
20,107
+3,000
+18% +$47.3K ﹤0.01% 1791
2025
Q4 		$263K Buy
17,107
+629
+4% +$10.6K ﹤0.01% 1635
2025
Q3 		$242K Buy
16,478
+1,599
+11% +$27.4K ﹤0.01% 1599
2025
Q2 		$271K Buy
+14,879
New +$303K ﹤0.01% 1383

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Lido Advisors's ADMA Position: Q2 2026 in Review

Lido Advisors increased its ADMA Biologics (ADMA) stake by 20% in Q2 2026, buying an estimated $37.1K and bringing the position to 24,174 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #1965.

Lido Advisors first reported a position in ADMA in Q2 2025 and has held it in 5 quarters since. The position peaked at $271K in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Lido Advisors held 24,174 shares of ADMA Biologics worth $202K as of Q2 2026.
  • Lido Advisors bought 4,067 ADMA Biologics shares in Q2 2026, an estimated $37.1K.
  • ADMA Biologics made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1965 holding.
  • Lido Advisors first reported a position in ADMA Biologics in Q2 2025 and has held it in 5 quarters since.
  • Lido Advisors's ADMA Biologics position peaked at $271K in Q2 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.